Glaukos

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Glaukos reports robust Q4 earnings, sets ambitious growth plans for 2023

Glaukos delivered strong financial performance in Q4 2022 and outlined ambitious plans for 2023, focusing on innovation and market expansion. Despite staffing challenges and operating expense growth, the company remains optimistic about its growth prospects. Opportunities in advancing key products and addressing market dynamics position Glaukos for continued success.

Glaukos reports strong Q1 earnings, eyes international market opportunities

Glaukos delivered robust financial results in Q1 2023, showcasing growth in key franchises and advancing its pipeline. The company faces challenges in operational efficiency and market expansion but holds opportunities in international markets and innovative product offerings. Overall, Glaukos remains well-positioned for future growth and success.

Glaukos reports record Q2 sales, eyes international growth opportunities

Glaukos delivered strong Q2 results, with a focus on strategic investments for iDose launch and maintaining growth momentum. Challenges include reimbursement changes and healthcare trend normalization. Opportunities lie in international expansion and new product launches.

Glaukos reports robust Q3 sales, eyes early glaucoma intervention

Glaukos shows strong performance with sales growth and strategic developments.
Facing challenges in market share and FDA concerns but seizing growth opportunities.
Confidence in ongoing projects and commitment to advancing glaucoma therapies.
Strategic focus on innovation and market expansion in the glaucoma sector.

Glaukos achieves record sales, focuses on innovation and market growth

Glaukos delivered strong financial performance, with a focus on innovation and market leadership in the ophthalmic space.
The company's strategic strengths lie in its product portfolio, market access initiatives, and commitment to driving change in the standard of care.
Challenges include managing physician time allocation, balancing growth strategies, and ensuring successful product launches.
Opportunities for Glaukos include increased adoption of innovative products, pipeline advancements, and continued investment in driving future growth.

Glaukos reports record sales and raises guidance for 2024

Glaukos is on track for strong financial performance with record sales and increased guidance. The company faces challenges with iDose adoption and reimbursement timelines but sees opportunities for growth in various product lines.

Glaukos reports record Q2 sales, raises guidance amid innovation focus

Glaukos delivered strong financial performance in Q2 2024, with record net sales and raised full year guidance, driven by robust sales across key franchises.
The company's focus on innovation, balance sheet strengthening, and market expansion positions it well for future growth and competitive advantage.
While facing regulatory and operational challenges, Glaukos has opportunities to capitalize on market trends, product adoption, and international expansion.
Navigating these challenges and leveraging opportunities will be crucial for Glaukos to sustain growth momentum and enhance shareholder value.

Glaukos reports record Q3 sales, eyes growth through product launches

Glaukos delivered strong financial performance in Q3 2024, with record net sales and raised full year guidance. The company's focus on product innovation, market expansion, and reimbursement strategies positions it well for future growth. While challenges in financial restructuring and market access exist, opportunities in product launches and international expansion offer promising prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-301 for the treatment of signs and symptoms of Dry Eye Disease (DED). GLK-301 is the first investigational drug candidate utilizing Glaukos' iLution platform's patented cream-b

Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-302 for the treatment of presbyopia. GLK-302 is the second investigational drug candidate utilizing Glaukos' iLution platform's patented cream-based drug formulations that are

Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iPRIME™ Viscodelivery System, a sterile, single-use, minimally-invasive device for the delivery of viscoelastic fluid during ophthalmic surgery. “Since the i

Glaukos Announces FDA 510(k) Clearance of iPRIME™

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W.

Glaukos Announces Retirement of William J. Link, Ph.D.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be highlighted in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 12–15, 2021 in New Orleans, Louisiana. Key Glaucoma Presentations: Daniela Alvarez-Ascencio,

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting

Despite reporting third-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.

Glaukos (GKOS) Gains 3.6% Despite Reporting a Loss in Q3

Glaukos Corporation (GKOS) CEO Tom Burns on Q3 2021 Results - Earnings Call Transcript

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2021. Key highlights include: Net sales growth of 15% to $74.7 million in Q3 2021, compared to $64.8 million in Q3 2020. Glaucoma net sales of $58.5 million and Corneal Health net sales of $16

Glaukos Corporation Announces Third Quarter 2021 Financial Results

CMS' final payment rates for 2022 spurred an analyst upgrade for Glaukos.

Why Glaukos Stock Is Soaring Today

Glaukos Corporation (NYSE: GKOS) shares have gained as investors cheer the final physician payment rates and outpatient facility fees issued by the Centers for Medicare & Medicaid Services (CMS) for 2022. See the 8K filing on the update.

Why Are Glaukos Shares Rallying Today?

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2021 financial results after the market close on Thursday, November 4, 2021. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on November 4, 2021. A link

Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the European Society of Cataract and Refractive Surgeons (ESCRS) Annual Meeting, being held October 8-11, 2021, in Amsterdam, Netherlands. Key Glaucoma Presentations: Papers Fa

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps' proprietary library of investigational phar

Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.

Glaukos Corp (NYSE:GKOS) has settled a patent infringement lawsuit with Ivantis Inc. The lawsuit was initiated by Glaukos in 2018 in the U.S. District Court for the Central District of California, Southern Division, concerning Ivantis' Hydrus Microstent. Under the agreement, Ivantis will pay Glaukos $60 million, $30 million of which will be paid by December 31, and the other $30 million to be paid by December 31, 2022.

Ivantis To Pay $60M In Patent Litigation Settlement With Glaukos

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a settlement agreement with Ivantis, Inc. agreeing to terminate the patent infringement lawsuit Glaukos initiated on April 14, 2018 in the U.S. District Court for the Central District of California, Southern Division, concernin

Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.

Glaukos (GKOS) submits PMA application to the FDA, which can enhance the company's deep portfolio of novel glaucoma surgical devices and sustained pharmaceuticals.

Glaukos (GKOS) Announces PMA Submission, Boosts iStent Platform

Glaukos Corp (NYSE: GKOS) has submitted a supplemental premarket approval (PMA) application to the FDA for its iStent infinite Trabecular Micro-Bypass System. Related Content:   William Blair Downgrades Glaukos After Disappointing CMS Rate

Glaukos Files Pre-Market Application For Intraocular Pressure Device

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has submitted a supplemental pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the iStent infinite™ Trabecular Micro-Bypass System. The iStent infinite is an investigational device designed for use in a st

Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today an unprecedented clinical data milestone of 200 peer-reviewed publications highlighting the efficacy and safety of iStent® technologies around the world. This achievement represents the largest, most diverse and longest-term body of clinical data for a

Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® Technologies

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

Here's Why You Should Retain Glaukos (GKOS) Stock Right Now

Despite reporting second-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.

Glaukos (GKOS) Stock Gains 0.1% Following Lower Loss in Q2

Glaukos Corporation's (GKOS) CEO Tom Burns on Q2 2021 Results - Earnings Call Transcript

Glaukos Corporation (NYSE:GKOS) posted a second-quarter adjusted EPS loss of $(0.11), ahead of $(0.28) consensus, and better than $(0.61) a year ago. Sales increased from $31.6 million to $78.1 million, where analysts were looking for sales of $71.4 million.

Glaukos Guided Below Consensus After Q2 Earnings; Analysts Cut Price Target

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2021. Key highlights include: Net sales growth of 147% to $78.1 million in Q2 2021, compared to $31.6 million in Q2 2020. Glaucoma net sales of $62.7 million and Corneal Health net sales of $15.4

News for Glaukos Stock (GKOS)